PI3Kδ Inhibition by Idelalisib in Patients with Relapsed Indolent Lymphoma

BACKGROUND: Phosphatidylinositol-3-kinase delta (PI3Kδ) mediates B-cell receptor signaling and microenvironmental support signals that promote the growth and survival of malignant B lymphocytes. In a phase 1 study, idelalisib, an orally active selective PI3Kδ inhibitor, showed antitumor activity in...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Gopal, Ajay K., Kahl, Brad S., de Vos, Sven, Wagner-Johnston, Nina D., Schuster, Stephen J., Jurczak, Wojciech J., Flinn, Ian W., Flowers, Christopher R., Martin, Peter, Viardot, Andreas, Blum, Kristie A., Goy, Andre H., Davies, Andrew J., Zinzani, Pier Luigi, Dreyling, Martin, Johnson, Dave, Miller, Langdon L., Holes, Leanne, Li, Daniel, Dansey, Roger D., Godfrey, Wayne R., Salles, Gilles A.
Formato: Artigo
Idioma:Inglês
Publicado em: 2014
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4039496/
https://ncbi.nlm.nih.gov/pubmed/24450858
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1056/NEJMoa1314583
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados